You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 10,363,226

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,363,226

Title:	Platelet membrane-coated drug delivery system
Abstract:	Disclosed herein is a platelet membrane-coated nanovehicle having an inner core comprising a drug delivery matrix, and an outer shell platelet membrane coating the inner core. The inner core can be any drug delivery matrix capable of delivering a therapeutic agent to a cell. The outer shell platelet membrane can be a natural or synthetic membrane comprising platelet proteins capable of interacting with cancer cells. Also disclosed is a method for treating cancer in a subject that involves administering to the subject a platelet membrane-coated nanovehicle disclosed herein. Also disclosed is a method for treating vascular disease in a subject that involves administering to the subject a platelet membrane-coated nanovehicle disclosed herein.
Inventor(s):	Gu; Zhen (Apex, NC), Hu; Quanyin (Raleigh, NC)
Assignee:	North Carolina State University (Raleigh, NC)
Application Number:	15/752,008
Patent Claims:	1. A platelet membrane-coated nanovehicle, comprising a) an inner core comprising a drug delivery matrix, wherein the drug delivery matrix comprises an antineoplastic therapeutic agent; and b) an outer shell platelet membrane coating the inner core, wherein the outer shell platelet membrane further comprises tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) and endogenous P-selectin protein. 2. The platelet membrane-coated nanovehicle of claim 1, wherein the antineoplastic drug is a hydrophobic small molecule. 3. The platelet membrane-coated nanovehicle of claim 2, wherein the anti-neoplastic drug is selected from the group consisting of paclitaxel, camptothecin, and docetaxel. 4. The platelet membrane-coated nanovehicle of claim 1, wherein the antineoplastic drug is a hydrophilic small molecule. 5. The platelet membrane-coated nanovehicle of claim 1, wherein the antineoplastic drug is selected from the group consisting of doxorubicin, cisplatin, and 5-fluorouracil. 6. The platelet membrane-coated nanovehicle of claim 1, wherein the outer shell platelet membrane comprises integrin .alpha..sub.IIb.beta..sub.3. 7. The platelet membrane-coated nanovehicle of claim 1, wherein the outer shell platelet membrane comprises a self-recognized immunomodulatory protein selected from the group consisting of CD47, CD55, and CD59. 8. The platelet membrane-coated nanovehicle of claim 1, wherein the outer shell platelet membrane further comprises a heterologous extracellularly active protein. 9. The platelet membrane-coated nanovehicle of claim 8, wherein the extracellularly active protein comprises a therapeutic antibody. 10. The platelet membrane-coated nanovehicle of claim 9, wherein the therapeutic antibody comprises cetuximab, trastuzumab, or a combination thereof. 11. The platelet membrane-coated nanovehicle of claim 1, wherein the drug delivery matrix further comprises a polymeric gel. 12. The platelet membrane-coated nanovehicle of claim 1, wherein the drug delivery matrix further comprises an inorganic particle. 13. The platelet membrane-coated nanovehicle of claim 1, wherein the drug delivery matrix further comprises a lipid particle. 14. The platelet membrane-coated nanovehicle of claim 1, wherein the drug delivery matrix further comprises a dendrimer particle. 15. A method comprising administering the platelet membrane-coated nanovehicle of claim 1 to a subject. 16. The method of claim 15, wherein the subject is suffering from cancer. 17. The method of claim 15, wherein the subject is suffering from a vascular disease.

Details for Patent 10,363,226

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2035-08-12
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2035-08-12
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2035-08-12
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2035-08-12
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2035-08-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.